C
Christine L Phillips
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 54
Citations - 653
Christine L Phillips is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 32 publications receiving 326 citations. Previous affiliations of Christine L Phillips include University of Cincinnati & University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Marcelo C. Pasquini,Zhen-Huan Hu,Kevin J. Curran,Theodore W. Laetsch,Frederick L. Locke,Rayne H. Rouce,Michael A. Pulsipher,Christine L Phillips,Amy K. Keating,Matthew J. Frigault,Dana Salzberg,Samantha Jaglowski,Joshua P. Sasine,Joseph Rosenthal,Monalisa Ghosh,Daniel J. Landsburg,Steven P. Margossian,Paul L. Martin,Manali Kamdar,Peiman Hematti,Sarah Nikiforow,Cameron J. Turtle,Miguel-Angel Perales,Patricia Steinert,Mary M. Horowitz,Amy Moskop,Lida Bubuteishvili Pacaud,Lan Yi,Raghav Chawla,Eric Bleickardt,Stephan A. Grupp,Stephan A. Grupp +31 more
TL;DR: This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials.
Journal ArticleDOI
Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis
Shannon L. Maude,Shannon L. Maude,Michael A. Pulsipher,Michael Boyer,Stephan A. Grupp,Stephan A. Grupp,Stella M. Davies,Christine L Phillips,Michael R. Verneris,Keith J. August,Krysta Schlis,Timothy A. Driscoll,Rajen Mody,Christian M. Capitini,Carl H. June,Bruce L. Levine,Patricia A. Wood,Lan Yi,John E. Levine,John E. Levine +19 more
TL;DR: In this first multicenter trial of CAR-modified T cell therapy, CTL019 therapy was feasible and efficacious, showing a high ORR with durable remissions in pediatric/young adult pts with R/R B-ALL.
Journal ArticleDOI
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults
Christine L Phillips,Stella M. Davies,Richard McMasters,Michael J. Absalon,Maureen M. O'Brien,Jun Mo,Randall Broun,Jeffrey A. Moscow,Teresa A. Smolarek,Ramiro Garzon,William Blum,Sebastian Schwind,Guido Marcucci,John P. Perentesis +13 more
TL;DR: Low‐dose decitabine has encouraging activity and tolerability in adults with acute myeloid leukaemia (AML), but paediatric experience is lacking, and eight patients with refractory/relapsed AML are reported on.
Journal ArticleDOI
Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.
Amy K. Keating,Nathan Gossai,Christine L Phillips,Christine L Phillips,Kelly W. Maloney,Kristen Campbell,Andrew Doan,Deepa Bhojwani,Michael J. Burke,Michael R. Verneris +9 more
TL;DR: Children treated with blinatumomab for B-ALL with MRD had few side effects and proceeded to hematopoietic cell transplant without delay and results in favorable leukemia-free survival, toxicity, and overall survival.
Journal ArticleDOI
A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study
Maryam Fouladi,John P. Perentesis,Christine L Phillips,Sarah Leary,Joel M. Reid,Renee M. McGovern,Ashish M. Ingle,Charlotte H. Ahern,Matthew M. Ames,Peter J. Houghton,L. Austin Doyle,Brenda J. Weigel,Susan M. Blaney +12 more
TL;DR: In this article, the authors report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose-limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK-2206, an AKT inhibitor, in children with refractory or recurrent malignancies.